Dr. Armstrong's expert knowledge and vast experience with amphotericin B have allowed him to speak previously with authority on its merits and demerits. According to his assessment, amphotericin B is a valuable drug, marred by severe toxicity. I shall attempt to explain, in this short presentation, why liposomes as vehicles in which to administer amphotericin B have the potential to redress this agent's principal deficiency.
No takes yet. Share an insight, caveat, or question.
G. B. Mackaness (1990) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: